Arquivamento definitivo - Art. 33 da LPI
#11.1.1
05/26/2026
RPI 2890
Application data
Number
112024017829Type
Filing
Publication
PCT
US2023014114 The application was abandoned: examination was not requested within the 36 months following the 02/28/2023 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.
Talk to a specialistLatest action published by the INPI: 05/26/2026. We update with every new RPI gazette, published weekly.
Applicants
MEI PHARMA, INC.
US
Inventors
D. G. (pessoa física)
US
R. G. (pessoa física)
US
IPC Classification
Priority claims
US
63/315,380 · 03/01/2022
Abstract
TERAPIA COMBINADA DE INIBIDOR de PI3K E INIBIDOR de PD-1. São fornecidos aqui métodos de tratamento de doenças ou distúrbios proliferativos (por exemplo, um câncer) em um paciente que deles necessita usando uma terapia combinada do Composto (I) ou um sal farmaceuticamente aceitável do mesmo e um inibidor de PD-1 (por exemplo, Pembrolizumab).
Publications in the Brazilian Industrial Property Gazette (RPI).
#11.1.1
05/26/2026
RPI 2890
#11.1
03/10/2026
RPI 2879
#1.3
12/17/2024
RPI 2815
#1.1
09/10/2024
RPI 2801
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.